Helicobacter pylori (H. pylori) is a Gram-negative bacterium which colonizes the human stomach. The ability of H. pylori to evade the host defense system and the emergence of antibiotic resistant strains result in bacteria persistence and chronic inflammation, which leads to both severe gastric and extra-gastric diseases. Consequently, innovative approaches able to overcome H. pylori clinical outcomes are needed. In this work, we develop a novel non-toxic therapy based on the synergistic action of H. pylori phage and lactoferrin adsorbed on hydroxyapatite nanoparticles, which effectively impairs bacteria colonization and minimizes the damage of the host pro-inflammatory response.

中文翻译：

---

控制幽门螺杆菌诱导的持续性炎症和定植的创新方法。

幽门螺杆菌（H. pylori）是一种革兰氏阴性细菌，定居于人的胃部。的能力幽门螺杆菌逃避宿主防御系统和抗生素耐药菌株的出现导致细菌持久性和慢性炎症，从而导致双方严重的胃和额外的胃疾病。因此，需要能够克服幽门螺杆菌临床结果的创新方法。在这项工作中，我们基于幽门螺杆菌噬菌体和吸附在羟基磷灰石纳米粒子上的乳铁蛋白的协同作用，开发了一种新型的无毒疗法，可有效削弱细菌的定殖并最大程度地减少宿主促炎反应的损害。